[A clinico-pathological study on prognosis in node-negative breast cancer].
In recent study, recurrence was seen in about 10% patients with node negative breast cancer during 10 years after operation. I evaluated prognostic factors including tumor diameter on the cut surface, histological infiltration diameter, histological malignancy, and expression of c-erbB-2 oncoprotein in 779 patients with node-negative breast cancer. The patient were operated from 1960 to 1972 at the Cancer Institute Hospital, Tokyo. The overall survival rate in this series was 88.6% at ten years. The survival rate at ten years for patients with tumor more than 21mm in size was 82.6%, and for those with tumor more than 11mm in filtrated size was 83.1%. On the other hand, marked fatty tissue infiltration, marked lymphatic vessel invasion, extensive histological invasion and numerous mitosis were associated with poor prognosis. The expression of c-erbB-2 oncoprotein correlated with recurrence within 5 years.
Saeki
K
K
Second Department of Surgery, Teikyo University School of Medicine, Japan.
D001943:Breast Neoplasms / Q000378:metabolism / Q000401:mortality / Q000473:pathology*; D018567:Breast Neoplasms, Male / Q000378:metabolism / Q000401:mortality / Q000473:pathology; D005260:Female; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology*; D008207:Lymphatic Metastasis; D008297:Male; D009361:Neoplasm Invasiveness; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D015996:Survival Rate
D018719:Erb-b2 Receptor Tyrosine Kinases